Genmab — April 2019

[E_L]

"7/2 11:09
af Sukkeralf
Jan said once that if Janssen continued in solid tumours it will be with sc dosing and first after approval i MM - no need to jeopadize with unpleasent deaths in a solid tumour trial " we are getting close to that…

[E_L]

Personally, I don't think JNJ need to wait for Isa trials, it may help their decisions, but i imagine they already know enough about the effect on solids to make up their own mind

[E_L]

52000 patients have been treated with Dara so far; surely some of them had (developed during treatment) solid cancers…

[E_L]

or thinks like this "29/3 16:52
af E L
it surprises me each time again, i see an update on the Dara/Atezo trial for NSCLC... (link) "

[Sukkeralf]

E L but Daras
main focus still would be to reactivate checkpoint inhibitors

[E_L]

yes, that is the most logical, for now, that would be a good start

[Sukkeralf]

404: This page could not be found.BerGenBio - Developing first-in-class AXL inhibitors for aggressive disease

BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers

(www.bergenbio.com)

[Sukkeralf]

Bergenbio præsenterede lidt AXL præklinik:

[Solsen]

Hov jeg ser der skete noget 6:55 - mon jeg stadig sov

[JKY_VH]

[Solsen]

Men som EL skriver så passer man sikkert på sikkerhedsprofilen i MM lige nu. Ikke for meget fnidder i andre indikationer lige nu, hvor godkendelser er på vej.

[polle1]

Nu må man jo ikke lokke pigerne, men jeg prøver nu alligevel : kom nu MAIA

[Bella1]

Det er nok lige op over, polle

[nohope]

Metoo -

[bibob]

Der ligger en blok på ca 9000 stk i 1185. mon ikke den bliver ædt.

[bibob]

https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=340933009&sourcecode=hugin

[Tandfeen-2]

Lidt skuffende vi falder på positiv dag

[Helge_LarsenPI-redaktør]

Genmab-aktien lever sit eget liv.

[E_L]

Salvage Daratumumab Reaches High ORR in Relapsed Myeloma Following Allogeneic SCT https://www.onclive.com/web-exclusives/salvage-daratumumab-reaches-high-orr-in-relapsed-myeloma-following-allogeneic-sct

[Plimsoller]

Status quo!